Cantor Fitzgerald issued a coverage report on AbCellera, a company whose shares trade on Nasdaq.
3 reports, 2 independent
Updated Oct 15
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald issued a coverage report on AbCellera, a company whose shares trade on Nasdaq.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cantor Fitzgerald
American financial services company
-
AbCellera
company in Vancouver, Canada
Related events
- Cantor Fitzgerald initiated stock coverage on AgomAB Therapeutics, and Director David Epstein acquired company stock.
- Cantor Fitzgerald issued a neutral rating and price target, while Sherry Group Inc. significantly increased its share holdings on October 10, 2026.
- Bambusa Therapeutics filed an S-1 registration statement with the SEC to pursue an IPO on Nasdaq, with Cantor Fitzgerald and UBS in the underwriting syndicate.
- Cantor Fitzgerald lowered its price target on MARA stock on October 21, 2026.
- Analysts at Cantor Fitzgerald provided research reports on AMD shares.